Federal Circuit Refuses To Rehear Teva On Inhaler Patents – Next Stop, Supreme Court?

PhRMA, AstraZeneca, And Sanofi Filed Amicus Brief In Favor Of En Banc Rehearing

Teva will have to delist its ProAir HFA inhaler patents from the FDA’s Orange Book by mid-March, as the Federal Circuit denied its petition for en banc rehearing. Will the Supreme Court listen?

Photo of the US Supreme Court
(Shutterstock)

More from Legal & IP

More from Products